10.20
-0.66 (-6.08%)
| Penutupan Terdahulu | 10.86 |
| Buka | 10.85 |
| Jumlah Dagangan | 2,366,201 |
| Purata Dagangan (3B) | 2,304,195 |
| Modal Pasaran | 1,859,667,072 |
| Harga / Pendapatan (P/E Ke hadapan) | 36.90 |
| Harga / Jualan (P/S) | 4.67 |
| Harga / Buku (P/B) | 107.68 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2026 |
| Margin Keuntungan | -20.25% |
| Margin Operasi (TTM) | -5.14% |
| EPS Cair (TTM) | -0.290 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 47.90% |
| Nisbah Semasa (MRQ) | 1.72 |
| Aliran Tunai Operasi (OCF TTM) | -26.71 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.90 M |
| Pulangan Atas Aset (ROA TTM) | -3.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Xeris Biopharma Holdings, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 4.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | 1.50 |
|
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.19% |
| % Dimiliki oleh Institusi | 54.46% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |